Curated News
By: NewsRamp Editorial Staff
March 18, 2025
Lexaria's DehydraTECH-Tirzepatide Capsules Show Promising Results in Comparison Study
TLDR
- DehydraTECH-tirzepatide oral capsules offer more consistent accumulation in bloodstream than Zepbound® injections, providing a potential advantage for faster and sustained drug delivery.
- The Study compared once-daily oral DehydraTECH-tirzepatide capsules with once-weekly injected Zepbound®, showing similar end-of-study blood-concentration levels and reduced adverse events with oral delivery.
- By demonstrating reduced side effects and similar efficacy as injected tirzepatide, Lexaria's oral capsules offer a promising alternative for patients, potentially improving treatment experiences and outcomes.
- Oral DehydraTECH-tirzepatide unexpectedly reached comparable blood-concentration levels to injected Zepbound®, showcasing a novel and efficient drug delivery method in the pharmaceutical field.
Impact - Why it Matters
This news highlights the groundbreaking potential of Lexaria's DehydraTECH technology in revolutionizing oral drug delivery, particularly in the weight loss and diabetes control markets. The positive outcomes of the study offer hope for a more effective and tolerable alternative to injected medications, signaling a significant advancement in pharmaceutical innovation.
Summary
Lexaria Bioscience Corp. announces positive pharmacokinetic results from a study comparing oral DehydraTECH-tirzepatide to injected Zepbound®, showing more consistent blood accumulation over one week. The oral capsules also reduced adverse events by 47% and offer a viable alternative to injections.
The study demonstrated that orally delivered DehydraTECH-tirzepatide reached similar blood concentrations as the injected drug, with reduced side effects and comparable glycemic performance indicators. Lexaria's CEO, Richard Christopher, expressed excitement over the results, highlighting the potential of DehydraTECH in the weight loss and diabetes control markets.
With the successful outcomes of the study, Lexaria aims to further evaluate DehydraTECH-tirzepatide in an Australian Phase 1b study to establish its effectiveness over an extended dosing duration, potentially revolutionizing oral drug delivery in the industry.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Lexaria's DehydraTECH-Tirzepatide Capsules Show Promising Results in Comparison Study
